Changlu Liu

Summary

Affiliation: Johnson and Johnson Pharmaceutical Research and Development
Country: USA

Publications

  1. doi request reprint 3,5-Dihydroxybenzoic acid, a specific agonist for hydroxycarboxylic acid 1, inhibits lipolysis in adipocytes
    Changlu Liu
    Janssen Research and Development, LLC, 3210 Merryfield Row, San Diego, CA 92121, USA
    J Pharmacol Exp Ther 341:794-801. 2012
  2. doi request reprint Lactate inhibits lipolysis in fat cells through activation of an orphan G-protein-coupled receptor, GPR81
    Changlu Liu
    Johnson and Johnson Pharmaceutical Research and Development LLC, San Diego, CA 92121, USA
    J Biol Chem 284:2811-22. 2009
  3. doi request reprint Oxysterols direct B-cell migration through EBI2
    Changlu Liu
    Johnson and Johnson Pharmaceutical Research and Development, L L C, 3210 Merryfield Row, San Diego, California 92121, USA
    Nature 475:519-23. 2011
  4. ncbi request reprint Identification of relaxin-3/INSL7 as an endogenous ligand for the orphan G-protein-coupled receptor GPCR135
    Changlu Liu
    Johnson and Johnson Pharmaceutical Research and Development, L L C, San Diego, California 92121, USA
    J Biol Chem 278:50754-64. 2003
  5. ncbi request reprint G-protein-coupled receptor (GPCR)-142 does not contribute to relaxin-3 binding in the mouse brain: further support that relaxin-3 is the physiological ligand for GPCR135
    Steven W Sutton
    Johnson and Johnson Pharmaceutical Research and Development, LLC, San Diego, CA 92121, USA
    Neuroendocrinology 82:139-50. 2005
  6. ncbi request reprint R3(BDelta23 27)R/I5 chimeric peptide, a selective antagonist for GPCR135 and GPCR142 over relaxin receptor LGR7: in vitro and in vivo characterization
    Chester Kuei
    Johnson and Johnson Pharmaceutical Research and Development, LLC, San Diego, California 92121, USA
    J Biol Chem 282:25425-35. 2007
  7. ncbi request reprint Relaxin-3/insulin-like peptide 5 chimeric peptide, a selective ligand for G protein-coupled receptor (GPCR)135 and GPCR142 over leucine-rich repeat-containing G protein-coupled receptor 7
    Changlu Liu
    Johnson and Johnson Pharmaceutical Research and Development, L L C, San Diego, CA 92121, USA
    Mol Pharmacol 67:231-40. 2005
  8. doi request reprint Identification of the domains in RXFP4 (GPCR142) responsible for the high affinity binding and agonistic activity of INSL5 at RXFP4 compared to RXFP3 (GPCR135)
    Jessica Zhu
    Johnson and Johnson Pharmaceutical Research and Development, L L C, 3210 Merryfield Row, San Diego, CA 92121, USA
    Eur J Pharmacol 590:43-52. 2008
  9. ncbi request reprint Molecular and pharmacological characterization of serotonin 5-HT2A and 5-HT2B receptor subtypes in dog
    Pascal Bonaventure
    Johnson and Johnson Pharmaceutical Research and Development, L L C, 3210 Merryfield Row, San Diego, CA 92121, USA
    Eur J Pharmacol 513:181-92. 2005
  10. ncbi request reprint Pharmacological characterization of relaxin-3/INSL7 receptors GPCR135 and GPCR142 from different mammalian species
    Jingcai Chen
    Johnson and Johnson Pharmaceutical Research and Development, L L C, 3210 Merryfield Row, San Diego, CA 92121, USA
    J Pharmacol Exp Ther 312:83-95. 2005

Collaborators

Detail Information

Publications25

  1. doi request reprint 3,5-Dihydroxybenzoic acid, a specific agonist for hydroxycarboxylic acid 1, inhibits lipolysis in adipocytes
    Changlu Liu
    Janssen Research and Development, LLC, 3210 Merryfield Row, San Diego, CA 92121, USA
    J Pharmacol Exp Ther 341:794-801. 2012
    ..Because 3-HBA and 3,5-DHBA are polyphenolic acids found in many natural products, such as fruits, berries, and coffee, it is intriguing to speculate that other heretofore undiscovered natural substances may have therapeutic benefits...
  2. doi request reprint Lactate inhibits lipolysis in fat cells through activation of an orphan G-protein-coupled receptor, GPR81
    Changlu Liu
    Johnson and Johnson Pharmaceutical Research and Development LLC, San Diego, CA 92121, USA
    J Biol Chem 284:2811-22. 2009
    ..Our results indicate that lactate suppresses lipolysis in adipose tissue through a direct activation of GPR81. GPR81 may thus be an attractive target for the treatment of dyslipidemia and other metabolic disorders...
  3. doi request reprint Oxysterols direct B-cell migration through EBI2
    Changlu Liu
    Johnson and Johnson Pharmaceutical Research and Development, L L C, 3210 Merryfield Row, San Diego, California 92121, USA
    Nature 475:519-23. 2011
    ....
  4. ncbi request reprint Identification of relaxin-3/INSL7 as an endogenous ligand for the orphan G-protein-coupled receptor GPCR135
    Changlu Liu
    Johnson and Johnson Pharmaceutical Research and Development, L L C, San Diego, California 92121, USA
    J Biol Chem 278:50754-64. 2003
    ..The identification of relaxin-3 as the ligand for GPCR135 provides the framework for the discovery of a new brainstem/hypothalamus circuitry...
  5. ncbi request reprint G-protein-coupled receptor (GPCR)-142 does not contribute to relaxin-3 binding in the mouse brain: further support that relaxin-3 is the physiological ligand for GPCR135
    Steven W Sutton
    Johnson and Johnson Pharmaceutical Research and Development, LLC, San Diego, CA 92121, USA
    Neuroendocrinology 82:139-50. 2005
    ..GPCR135 mRNA and GPCR135 receptor binding sites are most prominent in the mouse amygdala and hypothalamus. These data suggest that relaxin-3/GPCR135 is the receptor ligand pair with physiological relevance in mouse brain...
  6. ncbi request reprint R3(BDelta23 27)R/I5 chimeric peptide, a selective antagonist for GPCR135 and GPCR142 over relaxin receptor LGR7: in vitro and in vivo characterization
    Chester Kuei
    Johnson and Johnson Pharmaceutical Research and Development, LLC, San Diego, California 92121, USA
    J Biol Chem 282:25425-35. 2007
    ..Thus, R3(BDelta23-27)R/I5 should prove a useful tool for the further delineation of the functions of the relaxin-3/GPCR135 system...
  7. ncbi request reprint Relaxin-3/insulin-like peptide 5 chimeric peptide, a selective ligand for G protein-coupled receptor (GPCR)135 and GPCR142 over leucine-rich repeat-containing G protein-coupled receptor 7
    Changlu Liu
    Johnson and Johnson Pharmaceutical Research and Development, L L C, San Diego, CA 92121, USA
    Mol Pharmacol 67:231-40. 2005
    ....
  8. doi request reprint Identification of the domains in RXFP4 (GPCR142) responsible for the high affinity binding and agonistic activity of INSL5 at RXFP4 compared to RXFP3 (GPCR135)
    Jessica Zhu
    Johnson and Johnson Pharmaceutical Research and Development, L L C, 3210 Merryfield Row, San Diego, CA 92121, USA
    Eur J Pharmacol 590:43-52. 2008
    ..These results suggest that the N-terminus and EL2 domains of RXFP3 and RXFP4 are involved in ligand binding while TM2, 3, and 5 are critical for receptor activation...
  9. ncbi request reprint Molecular and pharmacological characterization of serotonin 5-HT2A and 5-HT2B receptor subtypes in dog
    Pascal Bonaventure
    Johnson and Johnson Pharmaceutical Research and Development, L L C, 3210 Merryfield Row, San Diego, CA 92121, USA
    Eur J Pharmacol 513:181-92. 2005
    ..The availability of the full sequence and pharmacology of the canine 5-HT2A and canine 5-HT2B receptors provides useful information for the interpretation of previous and future pharmacological studies of 5-HT2A/2B ligands in dog...
  10. ncbi request reprint Pharmacological characterization of relaxin-3/INSL7 receptors GPCR135 and GPCR142 from different mammalian species
    Jingcai Chen
    Johnson and Johnson Pharmaceutical Research and Development, L L C, 3210 Merryfield Row, San Diego, CA 92121, USA
    J Pharmacol Exp Ther 312:83-95. 2005
    ..Boels and Schaller recently reported bradykinin as a ligand for GPCR142 (also known as GPR100). In this report, we demonstrate that bradykinin activates neither GPCR135 nor GPCR142, whereas relaxin-3 does...
  11. ncbi request reprint INSL5 is a high affinity specific agonist for GPCR142 (GPR100)
    Changlu Liu
    Johnson and Johnson Pharmaceutical Research and Development, San Diego, California 92121, USA
    J Biol Chem 280:292-300. 2005
    ..The high affinity interaction between INSL5 and GPCR142 coupled with their co-evolution and partially overlapping tissue expression patterns strongly suggest that INSL5 is an endogenous ligand for GPCR142...
  12. ncbi request reprint Distribution of G-protein-coupled receptor (GPCR)135 binding sites and receptor mRNA in the rat brain suggests a role for relaxin-3 in neuroendocrine and sensory processing
    Steven W Sutton
    Neuroscience Group, Johnson and Johnson Pharmaceutical Research and Development, LLC, 3210 Merryfield Row, San Diego, CA 92121, USA
    Neuroendocrinology 80:298-307. 2004
    ....
  13. doi request reprint Probing the functional domains of relaxin-3 and the creation of a selective antagonist for RXFP3/GPCR135 over relaxin receptor RXFP1/LGR7
    Changlu Liu
    Johnson and Johnson Pharmaceutical Research and Development, LLC, San Diego, California 92121, USA
    Ann N Y Acad Sci 1160:31-7. 2009
    ..Ongoing and future in vivo studies using the selective agonist and antagonist for RXFP3 will shed light on the physiological role of the relaxin-3 system...
  14. ncbi request reprint Recent progress in relaxin-3-related research
    Changlu Liu
    Johnson and Johnson Pharmaceutical Research and Development, LLC, San Diego, CA 92121
    Ann N Y Acad Sci 1041:47-60. 2005
    ..Autoradiographic distribution of GPCR135 binding sites using [125I]R3/I5 in rat brain shows that GPCR135 receptor is most prominent in areas known for the processing of sensory signals...
  15. doi request reprint Identification of structural motifs critical for epstein-barr virus-induced molecule 2 function and homology modeling of the ligand docking site
    Li Zhang
    Janssen Pharmaceutical Research and Development, San Diego, California, USA
    Mol Pharmacol 82:1094-103. 2012
    ..This model of ligand docking yields important structural insight into the molecular mechanisms mediating EBI2 function and may facilitate future efforts to design novel therapeutic agents that target EBI2...
  16. ncbi request reprint Identification and pharmacological characterization of prokineticin 2 beta as a selective ligand for prokineticin receptor 1
    Jingcai Chen
    Pharmaceutical Research and Development, Johnson and Johnson LLC, 3210 Merryfield Row, San Diego, CA 92121, USA
    Mol Pharmacol 67:2070-6. 2005
    ..PKRs have been reported to couple to G(q) and G(i) proteins. In this report, we show that PKs not only stimulate Ca(2+) mobilization but also induce cAMP accumulation in PKR-expressing cells...
  17. doi request reprint Study of GPR81, the lactate receptor, from distant species identifies residues and motifs critical for GPR81 functions
    Chester Kuei
    Johnson and Johnson Pharmaceutical Research and Development, San Diego, CA 92121, USA
    Mol Pharmacol 80:848-58. 2011
    ..These findings help us better understand the interaction between lactate and GPR81 and provide useful information for GPR81 ligand design...
  18. doi request reprint Relaxin-3, INSL5, and their receptors
    Changlu Liu
    Johnson and Johnson Pharmaceutical Research and Development, LLC, San Diego, California 92121, USA
    Results Probl Cell Differ 46:213-37. 2008
    ..The availability of those pharmacological tools should greatly facilitate future studies of the physiology of GPCR135 and GPCR142...
  19. doi request reprint Mutagenesis studies of neuropeptide S identify a suitable peptide tracer for neuropeptide S receptor binding studies and peptides selectively activating the I(107) variant of human neuropeptide S receptor
    Diane Nepomuceno
    Johnson and Johnson Pharmaceutical Research and Development, L L C, San Diego, CA 92121, USA
    Eur J Pharmacol 635:27-33. 2010
    ....
  20. doi request reprint Metabolic and neuroendocrine responses to RXFP3 modulation in the central nervous system
    Steven W Sutton
    Johnson and Johnson Pharmaceutical Research and Development, LLC, San Diego, California 92121, USA
    Ann N Y Acad Sci 1160:242-9. 2009
    ..These data suggest relaxin-3, acting through RXFP3, is involved in coordinating stress, learning and memory, and feeding responses as predicted on the basis of neuroanatomy...
  21. ncbi request reprint Identification of relaxin-3/INSL7 as a ligand for GPCR142
    Changlu Liu
    Johnson and Johnson Pharmaceutical Research and Development, L L C, San Diego, California 92121, USA
    J Biol Chem 278:50765-70. 2003
    ..In this report, we show an additional receptor, GPCR142, which is also selectively activated by relaxin-3. However, the anatomical localization of GPCR142 suggests that GPCR142 may have different physiological functions...
  22. ncbi request reprint Neuronal hyperpolarization-activated pacemaker channels drive neuropathic pain
    Sandra R Chaplan
    Neuroscience, Johnson and Johnson Pharmaceutical Research and Development, San Diego, California 92121, USA
    J Neurosci 23:1169-78. 2003
    ..These findings suggest novel insights into the molecular basis of pain and the possibility of new, specific, effective pharmacological therapies...
  23. ncbi request reprint Molecular and pharmacological characterization of the mouse histamine H3 receptor
    Jingcai Chen
    Johnson and Johnson Pharmaceutical Research and Development, 3210 Merryfield Row, San Diego, CA 92121, USA
    Eur J Pharmacol 467:57-65. 2003
    ..Taken together, these findings allow a further appreciation of the histamine H(3) receptor at the molecular level and provide an additional species to assist in the pharmacological assessment of histamine H(3) receptor function...
  24. ncbi request reprint Identification and biological evaluation of 4-(3-trifluoromethylpyridin-2-yl)piperazine-1-carboxylic acid (5-trifluoromethylpyridin-2-yl)amide, a high affinity TRPV1 (VR1) vanilloid receptor antagonist
    Devin M Swanson
    Johnson and Johnson Pharmaceutical Research and Development L L C, 3210 Merryfield Row, San Diego, California 92121, USA
    J Med Chem 48:1857-72. 2005
    ....
  25. ncbi request reprint Behavioral characterization of mice lacking histamine H(3) receptors
    Hiroshi Toyota
    Johnson and Johnson Pharmaceutical Research and Development, San Diego, California 92121, USA
    Mol Pharmacol 62:389-97. 2002
    ..These data indicate that the H(3) receptor-deficient mouse represents a valuable model for studying histaminergic regulation of a variety of behaviors and neurotransmitter systems, including dopamine and acetylcholine...